Loading clinical trials...
Loading clinical trials...
A Phase 1b, Multicenter, Open-Label, Dose Finding Study to Investigate the Safety and Tolerability of a Single Intravenous Dose of SGT-501 in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia
Conditions
Interventions
SGT-501
Locations
5
United States
Boston Children's Hospital
Boston, Massachusetts, United States
Mayo Clinic
Rochester, Minnesota, United States
Cleveland Clinic
Cleveland, Ohio, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
St. Paul's Hospital
Vancouver, British Columbia, Canada
Start Date
February 23, 2026
Primary Completion Date
June 1, 2027
Completion Date
May 1, 2031
Last Updated
March 27, 2026
NCT07263139
NCT06661278
NCT04189822
NCT04650009
NCT02927223
Lead Sponsor
Solid Biosciences Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions